LLY
Eli Lilly and Company
NYSE: LLY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$934.60
+9.80% today
Updated 2026-04-29
Market cap
$760.43B
P/E ratio
37.03
P/S ratio
11.67x
EPS (TTM)
$22.99
Dividend yield
0.69%
52W range
$620 – $1,132
Volume
2.9M
Eli Lilly and Company (LLY) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.69B | $18.63B | $20.37B | $21.84B | $23.08B | $24.29B | $22.60B | $23.11B | $19.62B | $19.96B | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
| Revenue growth (YoY) | — | +18.8% | +9.3% | +7.2% | +5.7% | +5.2% | -6.9% | +2.3% | -15.1% | +1.7% | +6.3% | -5.9% | +7.6% | +3.8% | +9.9% | +15.4% | +0.8% | +19.6% | +32.0% | +44.7% |
| Cost of revenue | $3.55B | $4.25B | $4.38B | $4.25B | $4.37B | $5.07B | $4.80B | $4.91B | $4.93B | $5.04B | $5.71B | $4.45B | $4.68B | $4.72B | $5.48B | $7.31B | $6.63B | $7.08B | $8.42B | $10.56B |
| Gross profit | $12.14B | $14.38B | $16.00B | $17.59B | $18.71B | $19.22B | $17.81B | $18.20B | $14.68B | $14.92B | $15.51B | $15.53B | $16.81B | $17.60B | $19.06B | $21.01B | $21.91B | $27.04B | $36.62B | $54.62B |
| Gross margin | 77.4% | 77.2% | 78.5% | 80.6% | 81.1% | 79.1% | 78.8% | 78.8% | 74.9% | 74.8% | 73.1% | 77.7% | 78.2% | 78.8% | 77.7% | 74.2% | 76.8% | 79.2% | 81.3% | 83.8% |
| R&D | $3.13B | $3.49B | $3.84B | $4.33B | $4.88B | $5.02B | $5.28B | $5.53B | $4.73B | $4.80B | $5.31B | $5.10B | $5.05B | $5.59B | $5.98B | $6.93B | $7.19B | $9.31B | $10.99B | $13.34B |
| SG&A | $4.89B | $6.10B | $6.63B | $6.89B | $7.05B | $7.88B | $7.51B | $7.13B | $6.62B | $6.53B | $6.33B | $6.18B | $5.73B | $6.00B | $5.87B | $6.14B | $6.07B | $6.94B | $8.13B | $11.09B |
| Operating income | $4.13B | $4.80B | $5.53B | $6.37B | $6.77B | $6.32B | $5.02B | $5.55B | $3.33B | $3.59B | $3.87B | $4.25B | $6.03B | $6.00B | $7.21B | $7.93B | $8.65B | $10.79B | $17.50B | $29.70B |
| Operating margin | 26.3% | 25.8% | 27.1% | 29.2% | 29.3% | 26.0% | 22.2% | 24.0% | 17.0% | 18.0% | 18.2% | 21.3% | 28.0% | 26.9% | 29.4% | 28.0% | 30.3% | 31.6% | 38.9% | 45.6% |
| EBITDA | $4.93B | $5.85B | $43.30M | $6.92B | $8.04B | $6.91B | $7.05B | $7.50B | $4.53B | $4.38B | $5.06B | $4.10B | $5.53B | $6.90B | $8.91B | $8.04B | $8.66B | $8.57B | $15.23B | $27.94B |
| EBITDA margin | 31.4% | 31.4% | 0.2% | 31.7% | 34.8% | 28.4% | 31.2% | 32.4% | 23.1% | 21.9% | 23.8% | 20.5% | 25.7% | 30.9% | 36.3% | 28.4% | 30.3% | 25.1% | 33.8% | 42.9% |
| EBIT | $4.13B | $4.80B | $-1.08B | $5.62B | $6.71B | $5.54B | $5.59B | $6.05B | $3.15B | $2.95B | $3.56B | $2.53B | $3.92B | $5.67B | $7.59B | $6.50B | $7.14B | $7.04B | $13.46B | $26.37B |
| Interest expense | $0.00 | $0.00 | $228.30M | $261.30M | $185.50M | $186.00M | $177.80M | $160.10M | $148.80M | $161.20M | $185.20M | $225.00M | $242.50M | $400.60M | $359.60M | $339.80M | $331.60M | $485.90M | $780.60M | $795.30M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $2.66B | $2.95B | $-2.07B | $4.33B | $5.07B | $4.35B | $4.09B | $4.68B | $2.39B | $2.41B | $2.74B | $-204.10M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B |
| Net income growth (YoY) | — | +10.9% | -170.2% | +308.9% | +17.1% | -14.2% | -6.0% | +14.6% | -49.0% | +0.7% | +13.7% | -107.5% | +1683.5% | +157.4% | -25.5% | -9.9% | +11.9% | -16.1% | +102.1% | +94.9% |
| Profit margin | 17.0% | 15.8% | -10.2% | 19.8% | 22.0% | 17.9% | 18.1% | 20.3% | 12.2% | 12.1% | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |